Processing heterogeneous biomass: overcoming the hurdles in model building.

ABSTRACT: Plants have been developed as an alternative platform for the production of biopharmaceutical proteins, culminating recently with the FDA approval of the first plant-derived recombinant pharmaceutical enzyme for human use (ELELYSOÔ by Protalix Biotherapeutics). Among the many different plant-based technologies that have been proposed, transient expression mediated by Agrobacterium tumefaciens has proven to be particularly suitable for the rapid production of vaccines in response to emerging pandemics. However, one potential drawback of transient expression in whole plants is the large variation in recombinant protein expression levels among different leaves, which introduces a level of uncertainty in process design that can increase the regulatory burden and production costs. Transient exp

SUBMITTER: Buyel JF 

PROVIDER: S-EPMC3566015 | biostudies-literature | 2013 Jan-Feb

REPOSITORIES: biostudies-literature